Cabaletta Bio, INC Schedule 13G passive stakes

Cabaletta Bio, Inc. has disclosed that Cormorant Asset Management, LP, along with Bihua Chen, now beneficially owns 5.95% of the company's common stock, primarily through the exercise of warrants.

Bain Capital Life Sciences Opportunities III, L.P. has disclosed a beneficial ownership of 9.99% in Cabaletta Bio, Inc., primarily through warrants and common stock, subject to a beneficial ownership blocker.

Adage Capital Management, L.P. has reported a beneficial ownership of 8.43% in Cabaletta Bio, Inc., including shares issuable upon warrant exercise.

Norges Bank has reported beneficial ownership of 5.38% of Cabaletta Bio, Inc.'s common stock as of June 30, 2026, classifying itself as an investment adviser.

Vanguard Capital Management has reported beneficial ownership of over 8.29 million shares, representing 5.08% of Cabaletta Bio Inc.'s common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 1.3% of Cabaletta Bio, Inc.'s common stock as of June 30, 2026.

Prudential Financial, Inc. has filed a Schedule 13G reporting an 11.4% beneficial ownership stake in Cabaletta Bio, Inc.

Investment adviser Jennison Associates LLC has reported a beneficial ownership of 11.4% in Cabaletta Bio Inc common stock.

Cabaletta Bio, Inc. has disclosed that Cormorant Asset Management, LP and Bihua Chen now beneficially own 9.03% of the company's common stock, primarily through exercisable warrants.

Cormorant Asset Management and Bihua Chen report a 9.28% beneficial ownership stake in Cabaletta Bio, Inc., including shares from warrants.

T. Rowe Price Investment Management, Inc. has disclosed a 10.2% beneficial ownership stake in Cabaletta Bio Inc., primarily through its investment advisory services.

Alyeska Investment Group, L.P. and its affiliates reported a 6.03% beneficial ownership stake in Cabaletta Bio, Inc., comprising common stock and warrants.

Citadel entities and Kenneth Griffin have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.4% in Cabaletta Bio, Inc. as of September 30, 2025.

Cormorant Asset Management and Bihua Chen report a 9.99% beneficial ownership stake in Cabaletta Bio, Inc. through an amended Schedule 13G filing.

Prudential Financial Inc. reports an 8.9% beneficial ownership stake in Cabaletta Bio, Inc. through its subsidiaries, holding 12,584,537 common shares.

T. Rowe Price Investment Management, Inc. has disclosed an 11.3% beneficial ownership stake in Cabaletta Bio Inc. common stock.

T. Rowe Price Investment Management, Inc. has reported a 9.1% beneficial ownership stake in Cabaletta Bio Inc., holding 8,362,489 shares of common stock.

Jennison Associates LLC has disclosed an 8.9% beneficial ownership stake in Cabaletta Bio Inc., holding 12,584,537 shares of common stock.

Bain Capital Life Sciences Opportunities III, LP has disclosed a 9.99% beneficial ownership stake in Cabaletta Bio, Inc., comprising common stock and warrants.

Alyeska Investment Group, L.P. and its affiliates have disclosed a 9.9% beneficial ownership stake in Cabaletta Bio, Inc., totaling 8,904,367 shares.

Cormorant Asset Management, LP and Bihua Chen reported beneficial ownership of 5,000,000 shares, or 5.47%, of Cabaletta Bio, Inc. common stock.

Adage Capital Management, L.P. and its principals reported a 9.99% beneficial ownership stake in Cabaletta Bio, Inc., including shares from warrants.

Steven Nichtberger reports beneficial ownership of 3.3% of Cabaletta Bio, Inc. common stock as of June 30, 2025.

Jennison Associates LLC has disclosed a 7.2% beneficial ownership stake in Cabaletta Bio Inc., holding over 10.1 million shares of common stock.

Prudential Financial, Inc. has filed an amended Schedule 13G, disclosing a 7.4% beneficial ownership stake in Cabaletta Bio, Inc. as of June 30, 2025.

The Vanguard Group reported a 3.83% passive beneficial ownership stake in Cabaletta Bio Inc., holding 3,450,727 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 1.0% beneficial ownership stake in Cabaletta Bio, Inc. as of June 30, 2025.

Citadel Advisors LLC, Citadel Securities LLC, and affiliated entities, along with Kenneth Griffin, have disclosed a combined beneficial ownership of 5.2% in Cabaletta Bio, Inc., primarily for investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Cabaletta Bio, Inc. as of December 31, 2024.